India can give ‘emergency approval’ of corona vaccine

International Desk, Barta24.com
Photo: Collected

Photo: Collected

  • Font increase
  • Font Decrease

India may give 'emergency approval' to the corona vaccine ahead of schedule time. The Indian Council of Medical Research (ICMR) made the announcement on Thursday (August 20).

According to the ICMR, considering the situation, the antidote may be available in India much earlier than expected.

Director General of the Indian Council of Medical Research Balaram Varghese said that it takes 6-9 months for a third or final stage human trial of a vaccine to be completed. However, if the government decides, emergency approval may be considered.

The results of the first phase of human trials of Covaxin, an anti-corona vaccine made in India, have recently come to light. According to observers, these results are quite promising! The second phase of Covaxin's human trial has already begun. It is learned that a total of 1,100 volunteers will be vaccinated in two phases. The Indian Council of Medical Research has selected a total of 12 institutes, including the Nizam Institute of Medical Sciences in Hyderabad, AIIMS in Delhi and Patna, for the trial.

On the other hand, the trial of the first phase has been completed successfully by the DNA vaccine (ZyCov-D) made by Ahmedabad-based pharmaceutical company Zydus Cadillar. Zydus Cadila made corona vaccine (Zydus Cadila) according to rules of the corona vaccine (ZyCov-D) trial, three doses of antidotes should be given every 28 days. Volunteers were monitored for 28 days after vaccination. The trial of the second phase of the vaccine is also to be conducted under the same rules.

India Biotech's Covaxin and Zydus Cadilla Corona vaccine ZyCov-D's second phase of human trial is now nearing completion. The Indian news agency PTI reported on Wednesday that considering the current situation, the two vaccines are being considered for "emergency approval". Emergency approval of any antidote can be considered if the center so desires.